keyword
MENU ▼
Read by QxMD icon Read
search

basdai

keyword
https://www.readbyqxmd.com/read/28631697/-changes-in-the-serum-concentrations-of-adhesion-molecules-and-vascular-endothelial-growth-factor-in-active-ankylosing-spondylitis-patients-taking-amtolmetin-guacil-results-of-a-56-week-prospective-%C3%B0-%C3%B1-%C3%B0%C2%B5n-label-controlled-observational-study
#1
I Z Gaydukova, E V Khondkaryan, A V Aparkina, A P Rebrov
AIM: To estimate changes in the concentrations of adhesion molecules and vascular endothelial growth factor A after 30-day additional use of amtolmetin guacil (AMG) in patients with active ankylosing spondylitis (AS) who were unresponsive to previous one-year treatment with nonsteroidal anti-inflammatory drugs (NSAIDs). SUBJECTS AND METHODS: 20 patients with active AS who had not reached a BASDAI score <4.0 at week 52 of NSAID therapy and 10 healthy individuals matched for cardiovascular risk factors were examined...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28631696/-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-two-stages-of-disease
#2
D G Rumyantseva, T V Dubinina, A B Demina, O A Rumyantseva, E M Agafonova, A V Smirnov, Sh F Erdes
AIM: To compare the clinical manifestations of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nrAxSpA). SUBJECTS AND METHODS: A Moscow early spondyloarthritis cohort has now included 132 patients with axial spondyloarthritis, of whom 69 patients who have been followed up at least 12 months are to be involved in a preliminary analysis. The mean age at the time of inclusion in the study was 28.1±5.5 years; the mean disease duration was 24...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28630526/discriminating-value-of-calprotectin-in-disease-activity-and-progression-of-nonradiographic-axial-spondyloarthritis-and-ankylosing-spondylitis
#3
Jinxian Huang, Zhihua Yin, Guoxiang Song, Shengjin Cui, Jinzhao Jiang, Lijun Zhang
It has been controversial whether ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpA) are separate or different phases of radiographic progression. We determined that serum calprotectin level (ng/ml) was higher in AS (15.30 ± 6.49) and nr-axSpA (17.76 ± 8.59) patients than in healthy individuals (7.40 ± 2.67). No difference was observed in calprotectin level between these two groups. Elevated calprotectin was positively correlated with ESR, CRP, BASDAI, and ASDAS as well as SPARCC scoring and had no correlation with BASFI and mSASSS...
2017: Disease Markers
https://www.readbyqxmd.com/read/28605535/muscle-wasting-in-male-tnf-%C3%AE-blocker-na%C3%A3-ve-ankylosing-spondylitis-patients-a-comparison-of-gender-differences-in-body-composition
#4
Sebastián Ibáñez Vodnizza, Ingrid M Visman, Christiaan van Denderen, Willem F Lems, Francisca Jaime, Michael T Nurmohamed, Irene E van der Horst-Bruinsma
Objective.: To assess gender differences in body composition (BC) in a cohort of AS patients naïve to TNF-α blockers. Methods.: Patients included fulfilled the Modified New York criteria for AS. Demographic information and disease activity measures (ASDAS and BASDAI) were reported. BC was measured by whole body DXA. Body fat percentage (BF%), fat mass index (FMI), fat free mass index (FFMI) and android/gynoid fat ratio were reported and compared between men and women and with the reference population (percentiles)...
June 12, 2017: Rheumatology
https://www.readbyqxmd.com/read/28569568/performance-of-the-classification-criteria-in-patients-with-late-onset-axial-spondyloarthritis
#5
Louise T Bendahan, Natália P Machado, Jamille G Mendes, Thauana L Oliveira, Marcelo M Pinheiro
AIM: To evaluate the performance of four different classification criteria for spondyloarthritis (SpA) in patients with late-onset symptoms and to compare the clinical, laboratory and radiographic outcomes among the patients with symptoms before and after 45 years of age. PATIENTS AND METHODS: A total of 329 patients with SpA were enrolled in this prospective cohort. Patients with psoriatic arthritis, reactive arthritis, colitis associated arthritis and peripheral or undifferentiated SpA were excluded...
June 1, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28539676/results-from-polish-spondyloarthritis-initiative-registry-polspi-methodology-and-data-from-the-first-year-of-observation
#6
Zofia Guła, Tacjana Barczyńska, Marek Brzosko, Jerzy Gąsowski, Sławomir Jeka, Katarzyna Jodłowska-Cicio, Beata Kwaśny-Krochin, Piotr Leszczyński, Łukasz Lubiński, Katarzyna Łosińska, Katarzyna Pawlak-Buś, Hanna Przepiera-Będzak, Włodzimierz Samborski, Małgorzata Schlabs, Maciej Siedlar, Dorota Sikorska, Jerzy Świerkot, Małgorzata Węgierska, Piotr Wiland, Mariusz Korkosz
OBJECTIVES: Report on one-year results from the Polish Spondyloarthritis Initiative registry (PolSPI), containing the cross-sectional analysis of clinical and imaging data as well as database methodology. MATERIAL AND METHODS: The PolSPI registry includes patients with axial (axSpA) and peripheral (perSpA) spondyloarthritis according to ASAS classification criteria, and/or patients with ankylosing spondylitis according to modified New York criteria, psoriatic arthritis according to CASPAR criteria, arthropathy in inflammatory bowel disease, reactive arthritis, juvenile spondyloarthritis or undifferentiated spondyloarthritis...
2017: Reumatologia
https://www.readbyqxmd.com/read/28516874/long-term-effects-of-interleukin-17a-inhibition-with-secukinumab-in-active-ankylosing-spondylitis-3-year-efficacy-and-safety-results-from-an-extension-of-the-phase-3-measure-1-trial
#7
Xenofon Baraliakos, Alan J Kivitz, Atul A Deodhar, Jürgen Braun, James C Wei, Eumorphia Maria Delicha, Zsolt Talloczy, Brian Porter
OBJECTIVES: Secukinumab, a fully human anti-IL-17A monoclonal antibody, provided rapid and sustained improvements in signs and symptoms of ankylosing spondylitis (AS) over 2 years in the Phase 3 MEASURE 1 trial. Here, we report efficacy and safety after 3 years of treatment. METHODS: AS subjects completing 2 years of treatment every 4 weeks with subcutaneous secukinumab 150 or 75 mg (following intravenous loading or initial placebo treatment to 16/24 weeks) entered a separate 3-year extension study (NCT01863732)...
May 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28514405/-stable-high-interleukin-17a-concentration-in-patients-with-ankylosing-spondylitis-treated-with-tumor-necrosis-factor-%C3%AE-inhibitors-during-a-year
#8
I Z Gaydukova, A P Rebrov, A V Aparkina, E V Khondkaryan
AIM: To assess changes in the concentration of interleukin-17A (IL-17A) in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor-α (TNFα) inhibitors during a year. SUBJECTS AND METHODS: Examinations were made in 30 patients (22 (73.3%) men) aged 38.35±9.19 years with AS (modified New-York criteria, BASDAI ≥4.0; AS duration, 11.4±9.6 years) and in 20 healthy individuals (12 (60%) men) aged 40.1±7.7 years) (a control group). All the patients were treated with infliximab (remicade, MSD) 5 mg/kg body weight during a year according to the recommended regimen...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28507445/evaluation-of-fatigue-and-its-correlation-with-quality-of-life-index-anxiety-symptoms-depression-and-activity-of-disease-in-patients-with-psoriatic-arthritis
#9
Claudio Carneiro, Mario Chaves, Gustavo Verardino, Ana Paula Frade, Pedro Guimaraes Coscarelli, Washington Alves Bianchi, Marcia Ramos-E-Silva, Sueli Carneiro
BACKGROUND: Psoriatic arthritis is associated with psychosocial morbidity and decrease in quality of life. Psychiatric comorbidity also plays an important role in the impairment of quality of life and onset of fatigue. OBJECTIVES: This study aimed to assess the prevalence of fatigue in psoriatic arthritis patients and to correlate it to quality of life indexes, functional capacity, anxiety, depression and disease activity. PATIENTS AND METHODS: This cross-sectional study was performed on outpatients with psoriatic arthritis...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/28498975/sustained-efficacy-safety-and-patient-reported-outcomes-of-certolizumab-pegol-in-axial-spondyloarthritis-4-year-outcomes-from-rapid-axspa
#10
Désirée van der Heijde, Maxime Dougados, Robert Landewé, Joachim Sieper, Walter P Maksymowych, Martin Rudwaleit, Filip Van den Bosch, Jürgen Braun, Philip J Mease, Alan J Kivitz, Jessica Walsh, Owen Davies, Lars Bauer, Bengt Hoepken, Luke Peterson, Atul Deodhar
Objective.: The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA. Methods.: RAPID-axSpA was a phase 3 randomized trial, double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Patients had a clinical diagnosis of axSpA, meeting Assessment of SpondyloArthritis international Society (ASAS) criteria, and had active disease...
May 12, 2017: Rheumatology
https://www.readbyqxmd.com/read/28496443/higher-levels-of-secretory-iga-are-associated-with-low-disease-activity-index-in-patients-with-reactive-arthritis-and-undifferentiated-spondyloarthritis
#11
Fabián Salas-Cuestas, Wilson Bautista-Molano, Juan M Bello-Gualtero, Ivonne Arias, Diana Marcela Castillo, Lorena Chila-Moreno, Rafael Valle-Oñate, Daniel Herrera, Consuelo Romero-Sánchez
INTRODUCTION: Both reactive arthritis (ReA) and undifferentiated spondyloarthritis (uSpA) belong to the group of autoinflammatory diseases called spondyloarthritis (SpA). Hypotheses have been proposed about a relationship between the intestinal mucosa and inflammation of joint tissues. The role of immunoglobulin IgA or secretory immunoglobulin A (SIgA) in the inflammatory and/or clinical activity of patients with SpA remains poorly understood. OBJECTIVE: To evaluate the status of total IgA and SIgA, and the association among the levels of SIgA, IgA, IgA anti-Chlamydia trachomatis, and anti-Shigella spp...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28488046/features-of-the-achilles-tendon-paratenon-and-enthesis-in-inflammatory-rheumatic-diseases-a%C3%A2-clinical-and-ultrasonographic-study
#12
H Harman, E Süleyman
AIM: We analyzed the ultrasonographic (US) features of the Achilles tendon (AT), paratenon (AP), and enthesis in patients with axial spondyloarthropathies (SpA) and rheumatoid arthritis (RA), and compared these to healthy subjects. Relationships between these findings and clinical and functional parameters were identified. METHODS: The study included 40 axial SpA and 27 RA patients, as well as 30 healthy subjects. Clinical evaluation relied on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), AS Quality of Life Questionnaire (ASQoL), Disease Activity Score 28 (DAS28), and Health Assessment Questionnaire (HAQ), as well as on a visual analog scale (VAS) for entheseal pain and the Madrid Sonographic Enthesistis Index (MASEI)...
May 9, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28482137/effects-of-long-term-etanercept-treatment-on-clinical-outcomes-and-objective-signs-of-inflammation-in-early-non-radiographic-axial-spondyloarthritis-104-week-results-from-the-embark-study
#13
Maxime Dougados, Désirée van der Heijde, Joachim Sieper, Jürgen Braun, Gustavo Citera, Jan Lenaerts, Filip van den Bosch, James Cheng-Chung Wei, Ron Pedersen, Randi Bonin, Heather Jones, Lisa Marshall, Isabelle Logeart, Bonnie Vlahos, Jack F Bukowski, Walter P Maksymowych
OBJECTIVE: To evaluate the long-term clinical and imaging efficacy of etanercept in patients with early, active non-radiographic axial spondyloarthritis (nr-axSpA). METHODS: Adult patients who satisfied Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA, but not modified New York radiographic criteria, with symptom duration >3 months to <5 years, and who were unresponsive to ≥2 NSAIDs, received double-blind etanercept 50 mg/week or placebo for 12 weeks, followed by open-label etanercept 50 mg/week to week 104...
May 8, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28434410/dosage-and-duration-of-etanercept-therapy-for-ankylosing-spondylitis-a-meta-analysis
#14
Heeyoung Lee, Younjoo Jung, Seungyeon Song, Jihyung Lee, Hyunjun Shim, Wonku Kang, Eunyoung Kim
OBJECTIVES: We conducted a meta-analysis of recently published randomized controlled trials (RCTs) to identify the most effective and safe etanercept dosing regimen and duration of therapy for the treatment of patients with ankylosing spondylitis (AS). METHODS: We systematically reviewed PubMed, Embase, Cochrane Library, and Web of Science databases for RCTs. The proportion of patients attaining 20 percent improvement (according to the Spondyloarthritis International Society response criteria [ASAS 20]) was evaluated as a primary outcome...
April 24, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28421263/bone-mineral-density-and-fracture-risk-in-ankylosing-spondylitis-a-meta-analysis
#15
Cara Pray, Neelufor Irene Feroz, Nisha Nigil Haroon
We conducted a meta-analysis of studies to examine the risk of vertebral and non-vertebral fractures in patients with ankylosing spondylitis (AS). Additionally, we evaluated the risk factors of vertebral fractures in AS. Two authors independently searched Embase and Medline for studies that had assessed the risk of fractures in patients with AS. Twenty-two studies were eligible for the meta-analysis. Patients with AS had high frequency of vertebral fractures [OR (95% CI): 1.96 (1.52-2.51)]. Major risk factors for vertebral fractures in patients with AS include low BMD at the femoral neck and total hip, male gender, longer disease duration, higher BASDAI, higher BASRI, and possibly inflammatory bowel disease...
April 18, 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/28403136/influence-of-cyp2c9-and-cox-2-genetic-polymorphisms-on-clinical-efficacy-of-non-steroidal-anti-inflammatory-drugs-in-treatment-of-ankylosing-spondylitis
#16
Yu Wang, Xiao-Dong Yi, Hai-Lin Lu
BACKGROUND The aim of this study was to evaluate the relationships of CYP2C9 and COX-2 genetic polymorphisms with therapeutic efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) in treatment of ankylosing spondylitis (AS). MATERIAL AND METHODS We enrolled 130 AS inpatients and outpatients in the Arthritis and Rheumatism Department of Peking University First Hospital and 106 healthy people getting routine check-ups between September 2013 and July 2014. CYP2C9 and COX-2 genetic polymorphisms were detected by PCR-RFLP...
April 12, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28379663/erectile-dysfunction-in-ankylosing-spondylitis-patients
#17
Thiago Santana, Thelma Skare, Vitor Steil Delboni, Juliana Simione, Ana Paula B Campos, Renato Nisihara
BACKGROUND: Rheumatic diseases such as ankylosing spondylitis (AS) may be associated with sexual dysfunction. AIM: To study erectile function of a group of Brazilian AS patients comparing them with controls. MATERIALS AND METHODS: This was a cross sectional study approved by the local Committee of Ethics in Research. The questionnaire IIEF (International Index of Erectile Function) was applied to 40 AS patients and 40 healthy controls. AS patients had determination of disease activity (through BASDAI or Bath Ankylosing Spondylitis Disease activity index), ASDAS (Ankylosing Spondylitis Disease Activity Score, MASES or Maastricht Ankylosing Spondylitis Score and SPARCC or Spondyloarthritis Research Consortium of Canada), function (through BASFI or Bath Ankylosing Spondylitis Functional Index and HAQ or Health Assessment Questionnaire) and BASMI (Bath Ankylosing Spondylitis Metrological Index)...
April 6, 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/28378098/association-of-obesity-with-patient-reported-outcomes-in-patients-with-axial-spondyloarthritis-a-cross-sectional-study-in-an-urban-asian-population
#18
Yi Xuan Lee, Yu Heng Kwan, Wan Yu Png, Ka Keat Lim, Chuen Seng Tan, Nai Lee Lui, Eng Hui Chew, Julian Thumboo, Truls Østbye, Warren Fong
To determine if obesity is associated with poorer patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA), we conducted a cross-sectional study using data of the PRESPOND registry from a tertiary referral center in Singapore between 2011 and 2015. Demographics, clinical, and PRO variables were collected. Patients were divided into three categories: normal (BMI < 23 kg/m(2)), overweight (23 kg/m(2) ≤ BMI < 27.5 kg/m(2)) and obese (BMI ≥ 27.5 kg/m(2)), using Asian BMI classification...
April 4, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28362980/role-of-th1-th2-cytokines-in-the-diagnosis-and-prognostic-evaluation-of-ankylosing-spondylitis
#19
J T Wen, D H Zhang, P F Fang, M H Li, R J Wang, S H Li
Ankylosing spondylitis (AS), a progressive disease of the spine, manifests as peripheral arthritis with tendon and ligament inflammation that restricts activity. AS is a rheumatoid autoimmune disease although the rheumatoid factor is absent in patients with AS. It is characterized by inflammatory changes such as elevated levels of serum inflammatory factors. The roles of Th1 and Th2 cytokines in autoimmune diseases are well known. However, the roles of these cytokines in the diagnosis and prognosis of AS is poorly understood...
March 16, 2017: Genetics and Molecular Research: GMR
https://www.readbyqxmd.com/read/28293446/real-life-experience-of-using-conventional-disease-modifying-anti-rheumatic-drugs-dmards-in-psoriatic-arthritis-psa-retrospective-analysis-of-the-efficacy-of-methotrexate-sulfasalazine-and-leflunomide-in-psa-in-comparison-to-spondyloarthritides-other-than-psa
#20
Euthalia Roussou, Aicha Bouraoui
OBJECTIVE: With the aim of assessing the response to treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs) used in patients with psoriatic arthritis (PsA), data on methotrexate, sulfasalazine (SSZ), and leflunomide were analyzed from baseline and subsequent follow-up (FU) questionnaires completed by patients with either PsA or other spondyloarthritides (SpAs). MATERIAL AND METHODS: A single-center real-life retrospective analysis was performed by obtaining clinical data via questionnaires administered before and after treatment...
March 2017: European Journal of Rheumatology
keyword
keyword
116433
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"